

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form 425

SYNCOR INTERNATIONAL CORP /DE/  
Form 425  
December 04, 2002

Filed by Cardinal Health, Inc.  
Pursuant to Rule 425 under the Securities Act of 1933

Subject Company: Syncor International Inc.  
Commission File No. 000-08640

[Cardinal Health logo]

[images of laboratory and lab workers]

MERRILL LYNCH  
HEALTH CARE SERVICES CONFERENCE

George L. Fotiades  
Pharmaceutical Technologies and Services

December 4, 2002

FORWARD-LOOKING INFORMATION

-----  
Except for historical information, all other information in this presentation consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships, changes in the distribution outsourcing patterns for health-care products and/or services, the costs and other effects of governmental regulation and legal and administrative proceedings, and general economic and market conditions. Cardinal Health undertakes no obligation to update or revise any forward-looking statements.

Information regarding the identity of the persons who may, under SEC rules, be deemed to be participants in the solicitation of stockholders of Syncor International Corporation ("Syncor") in connection with the proposed merger, and their interests in the solicitation, is set forth in the definitive proxy statement/prospectus dated October 16, 2002 mailed to Syncor stockholders on October 17, 2002 and filed with the SEC as well as supplemental proxy material dated, mailed and filed with the SEC on November 25, 2002. Additional proxy materials will be filed with the SEC shortly. Cardinal Health, Inc. ("Cardinal Health") has filed a registration statement on Form S-4 in connection with the transaction. Investors and security holders of Syncor are urged to read the definitive proxy statement/prospectus and supplemental proxy material because it contains important information about Cardinal Health, Syncor and the transaction. Investors and security holders may obtain a free copy of the proxy statement/prospectus and the supplemental proxy material, as well as additional proxy materials when they are filed, at the SEC's web site at [www.sec.gov](http://www.sec.gov). A free copy of the proxy statement/prospectus and the supplemental proxy material, as well as any additional proxy materials once they are filed, may also be obtained from Cardinal Health or Syncor. Cardinal Health and Syncor and their respective executive officers and directors may be deemed to be participants in

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form 425

the solicitation of proxies from the stockholders of Syncor in favor of the transaction. In addition to the registration statement on Form S-4 filed by Cardinal Health in connection with the transaction, and the proxy statement/prospectus and supplemental proxy material mailed to the stockholders of Syncor in connection with the transaction, as well as any additional proxy materials once they are filed, each of Cardinal Health and Syncor file annual, quarterly and special reports, proxy and information statements, and other information with the SEC. Investors may read and copy any of these reports, statements and other information at the SEC's public reference room located at 450 5th Street, N.W., Washington, D.C., 20549. Investors should call the SEC at 1-800-SEC-0330 for further information. The reports, statements and other information filed by Cardinal Health and Syncor with the SEC are also available for free at the SEC's web site at www.sec.gov. A free copy of these reports, statements and other information may also be obtained from Cardinal Health or Syncor. Investors should read the proxy statement/prospectus, the supplemental proxy materials, as well as any additional proxy materials once they are filed, carefully before making any voting or investment decision.

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 2

RECENT EVENTS

-----

SYNCOR TRANSACTION

- o Agreement on New Exchange Ratio
- o Comfortable moving forward
- o International rationalization will continue
- o Strong strategic rationale

-----[Images of laboratory and lab workers]

[Cardinal Health Logo] 3

CARDINAL HEALTH -- A WORLD-CLASS COMPANY

-----

- o Distribution, manufacturing, and consulting [Image from annual report]
- o 50,000 associates on five continents
- o Annual revenues: > \$44 billion
- o Operating earnings: approximately \$2 billion
- o 15 years of > 20 percent EPS growth

- 99% OF OPERATING EARNINGS FROM BUSINESSES  
WITH LEADING MARKET SHARE


-----[Images of laboratory and lab workers]

[Cardinal Health Logo]

4

OUR STRATEGY IS TO...

-----  
 BE THE PREFERRED HEALTH CARE SERVICE PROVIDER -  
 UPSTREAM AND DOWNSTREAM



----> UNIQUELY POSITIONED TO PROVIDE SOLUTIONS

-----[Images of laboratory and lab workers]

[Cardinal Health Logo]

5

PHARMACEUTICAL TECHNOLOGIES & SERVICES

- |  |                              |
|--|------------------------------|
| o MANUFACTURE & PACKAGE OVER \$15 BILLION IN PRODUCT VALUE | REVENUES<br>\$1.5B           |
| o TOUCHED OVER 50% OF NDAS APPROVED IN LAST 3 YEARS        | CAPABILITIES<br>-----        |
| o PROPRIETARY DRUG DELIVERY TECHNOLOGIES                   | - PHARMACEUTICAL DEVELOPMENT |
| o LEADER IN MEDICAL EDUCATION                              | - ORAL TECHNOLOGIES          |
| o 10,000 EMPLOYEES SERVING GLOBAL MARKETS                  | - STERILE TECHNOLOGIES       |
|  | - PACKAGING                  |
|  | - SALES & MARKETING          |

[Pie graph depicting the following:]

OPERATING EARNINGS CONTRIBUTION 13%

-----[Images of laboratory and lab workers]

[Cardinal Health logo]

6

FACTORS DRIVING PTS TODAY

- 
- o Big pharma pipeline needs
    - Extending current product assets

- o FDA compliance scrutiny
  - Creating outsource opportunities
- o Biotech pipeline growth
  - Needs for resources and capabilities
- o Consolidation (service providers)
  - Cost of scale & compliance -- acquisition opportunities

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 7

PHARMACEUTICAL TECHNOLOGIES AND SERVICES

HOW DO WE WORK WITH CUSTOMERS?

-----

Provide integrated, enabling technologies and services that bring quality products to market faster and deliver greater value.

- o SPEED, FLEXIBILITY, HIGHEST STANDARDS OF QUALITY
- o FULL DEVELOPMENT PROGRAMS OR STAND ALONE PROJECTS
- o STERILE, ORAL, POTENT, RADIO-PHARM, CYTOTOXIC SOLUTIONS
- o COMMERCIAL MANUFACTURING AND PACKAGING
- o SPECIALTY DISTRIBUTION AND COMMERCIAL LAUNCH PROGRAMS

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 8

PHARMACEUTICAL TECHNOLOGIES AND SERVICES

UNMATCHED BREADTH

-----

DISCOVERY - DEVELOPMENT - COMMERCIAL - SALES - DISTRIBUTION  
MFG AND AND  
PACKAGING MARKETING

PHARMACEUTICAL TECHNOLOGIES & SERVICES

CARDINAL HEALTH

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 9

LEADERSHIP - PROPRIETARY MANUFACTURING

---

Oral Technologies                   o Encapsulation technologies for > solubility  
   o Particle coating for controlled release  
   o Fast disperse with Zydis(R) format

Sterile Technologies               o Aseptic blow/fill/seal  
   o Lyophilization

Packaging                           o Pharmaceutical packaging & components

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 10

LEADERSHIP - PROPRIETARY SERVICES

---

/	\	/	\
Pharma Development		/ o Complete range of analytical and	\
		developmental services	\
		o Virtually all dosage forms	\
\	/	\	/
-----	-----	-----	-----

/	\	/	\
Healthcare		/ o Medical education services	\
Marketing		o Contract sales support	\
Services		\	/
\	/	\	/
-----	-----	-----	-----

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 11


PTS BUSINESS MODEL

---

- v INVEST in proprietary businesses with great growth prospects
- v INTEGRATE offering to create more customer value
- v ENGAGE early in the drug's development life

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form 425

- v CREATE downstream manufacturing/packaging relationships
- v CONNECT multiple customer touch-points and cross-sell new business



[Cardinal Health logo]

12

RECENT DEVELOPMENTS

- o Generic isotretinoin approved by FDA. December 2 launch.
- o Claritin Redi-Tabs OTC approved by FDA.
- o Expanding lyophilization capacity:
  - Albuquerque (Spring 2003)
  - North Raleigh opening (Fall 2003)
- o Expanding Phase 1/Phase 2 biotech development capability in San Diego
- o Investment in Gala gene expression technology
- o NJ Development Center pilot plant is now operational

-----[Images of laboratory and lab workers]

[Cardinal Health logo]

13

BASE AND NEW/PENDING BUSINESS

	ORAL	STERILE	PACKAGING
EXISTING PRODUCTS	Kaletra	Xopenex	Celebrex
	Advil	Xalatan	Maxalt
	Claritin	Pulmozyme	Enbrel
	Maxalt		Avonex
	Zyprexa	Tobi	Concerta

Edgar Filing: SYNCOR INTERNATIONAL CORP /DE/ - Form 425

	Detrol LA		
-----			
PENDING/ NEW FY 03	Isotretinoin Generic Clarinetx Claritin OTC New Zydis CNS	(2) New Injectables (2) New Generic Respiratory	Bextra Zetia Evra Actos FluMist

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 14

PTS GROWTH DRIVERS - FY 2003

-----

- o Growth of core Rx brands
- o New product launches
- o Development services growth
- o Demand for sterile manufacturing capacity
- o Cross-selling momentum

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 15

PTS FUTURE FOCUS

-----

- o Grow development services (e.g. pulmonary, biotech)
- o Expand proprietary manufacturing (e.g. sterile, Zydis)
- o Expand sales & marketing presence in Europe and Japan
- o Develop/acquire proprietary technologies (e.g. Gala)
- o Continue to integrate capabilities (e.g. worldwide implementation of JD Edwards)

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 16

[Cardinal Health logo]-----

-----

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 17

KEY DRIVERS FOR FISCAL 2003

- o Capitalize on Generic Bubble
- o Med-Surg Distribution Driving Self Mtd Strategy
- o Product launches from strong PTS pipeline
- o Strong demand for patient safety and MedStation
- o Cross selling leverage
- o Strategic acquisitions

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 18

FISCAL 2003  
CONSOLIDATED OUTLOOK\*

	FY '03 GUIDANCE
Revenue	14-16%
Operating Earnings*	18-20%
Net Earnings*	20-22%
Diluted EPS*	20-22%

\*excluding special items

-----[Images of laboratory and lab workers]

[Cardinal Health logo] 19

-----  
[Cardinal Health logo]



A HISTORY OF PERFORMANCE

-----[Images of laboratory and lab workers]

[Cardinal Health logo]

20